Related Experiment Video
Updated: Jul 3, 2026
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
Signaling through CD80: an approach for treating lymphomas
Manzoor A Mir1, Javed N Agrewala
1Institute of Microbial Technology, Sector 39A, Chandigarh-160036, India.
Background:
One of the mechanisms by which tumors evade the immune system is by downregulating the expression of costimulatory molecules like CD80 and CD86. The role of CD80 in the activation of T cells is well established, and current studies are exploring its role in cancer.
Objective:
To examine the possible role of CD80 signaling in generating an effective immune response against cancer cells.
Methods:
Many reports have described the influence of CD80 on the growth of B cell and follicular lymphomas. Signaling through CD80 in B cell lymphomas can retard their proliferation by upregulating expression of pro-apoptotic molecules and downregulating antiapoptotic molecules and can therefore induce apoptosis. Recently, a Phase I/II study of treatment with CD80-specific antibody has shown it to be quite effective in relapsed and refractory follicular lymphoma patients.
Conclusion:
This study shows that anti-CD80 immunotherapy may have a potent role in treating CD80-bearing cancer cells.
Insights
Targeting CD80 (cluster of differentiation 80) with immunotherapy shows promise for treating cancers. This approach may help generate effective immune responses against CD80-expressing tumors.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumors evade immune detection by reducing costimulatory molecules like CD80 and CD86.
- CD80 plays a crucial role in T-cell activation, with ongoing research into its cancer implications.
Purpose of the Study:
- To investigate the potential role of CD80 signaling in eliciting an effective anti-cancer immune response.
Main Methods:
- Reviewed literature on CD80's impact on B-cell and follicular lymphoma growth.
- Examined CD80 signaling's effects on apoptosis-related molecules in lymphomas.
- Considered findings from a Phase I/II study of CD80-specific antibody treatment.
Main Results:
- CD80 signaling can inhibit lymphoma proliferation by modulating apoptotic pathways.
- A CD80-specific antibody demonstrated significant efficacy in relapsed/refractory follicular lymphoma patients.
Conclusions:
- Anti-CD80 immunotherapy presents a potential therapeutic strategy for cancers expressing CD80.
